Cell Impact (OSTO:CI) Total Operating Expense: kr121.22 Mil (TTM As of Mar. 2026)


What is Cell Impact Total Operating Expense?

Cell Impact OSTO:CI -1.66% Total Operating Expense is kr121.22 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

Cell Impact's Total Operating Expense for the three months ended in Mar. 2026 was kr17.76 Mil. Cell Impact's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr121.22 Mil.

Cell Impact Total Operating Expense Related Terms

Cell Impact Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Cell Impact's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Impact Total Operating Expense Chart

Cell Impact Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.92 141.01 144.94 104.44 122.83

Cell Impact Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.37 19.22 20.74 63.49 17.76

Cell Impact Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr121.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr121.22 Mil mean?
Cell Impact (OSTO:CI) has a Total Operating Expense of kr121.22 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Cell Impact and its competitors.
Is Cell Impact's Total Operating Expense too high?
Cell Impact's current Total Operating Expense is kr121.22 Mil.
How does Cell Impact's Total Operating Expense compare to CRS and ATI?
Cell Impact's Total Operating Expense of kr121.22 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for an Industrial Products company?
A good Total Operating Expense depends on the Industrial Products industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Cell Impact and its competitors. Cell Impact's current Total Operating Expense is kr121.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Impact stock overvalued right now?
Based on GuruFocus' analysis, Cell Impact (OSTO:CI) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.06, compared to a current price of kr0.08 — trading 28% above its estimated fair value. The current Total Operating Expense is kr121.22 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Cell Impact (OSTO:CI), the current Total Operating Expense is kr121.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Impact Business Description

Other Exchanges ICL:Germany
Address Kallmossvagen 7A, Karlskoga, SWE, 691 52
Cell Impact develops and manufactures flow plates for fuel cells and electrolyzers using materials such as graphite, stainless steel, and titanium. The company has developed and patented a high-velocity forming method, known as Cell Impact Forming, which enables the production of flow plates with advanced designs. Geographically, it operates in Sweden, Asia, the U.S., and Other Europe. It generates the majority of its revenue from Sweden.